Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 6, 2024
Daily News
June 6, 2024
- Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally
June 6, 2024
- Japan Eases Rule on Regulatory Submissions for Combination Therapies
June 6, 2024
- TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
- Shionogi to Open Antimicrobial R&D Center in San Diego
June 6, 2024
- Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
June 6, 2024
- PeptiDream Doses 1st Patient with CA9-Targeted Radiopeptide
June 6, 2024
- Japan Vaccine Market Projected to Top 280 Billion Yen in FY2024: Fuji Keizai
June 6, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…